Receptors and Their Modulation

  • F. X. Caroli-Bosc
  • P. Hastier
  • A. G. Harris
  • P. Gaudray
  • D. Balas
  • J. P. Delmont
Conference paper


The potential for hormonal intervention in cancer was identified as early as 1895, even before the concept of hormones was established. Indeed, we know that the first hormone was discovered only in 1902 (secretin, by Bayliss and Starling). The Scottish surgeon Beatson performed a bilateral ovarectomy in a young woman with an enormous cancer of the breast. The tumor regressed spectacularly. Subsequently, other hormonal actions on cancer were made possible (prostate, endometrial, thyroid), and it was extablished that this action was modulated by the presence of hormonal receptors in the cancerous tissue [1] (Figs. 1,2).


Pancreatic Cancer Pancreatic Cancer Cell Pancreatic Carcinoma Human Pancreatic Cancer Exocrine Pancreas 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McGuire WL (1978) Hormone receptors: their role in predincting prognosis and response to endocrine therapy. Semin Oncol 5:428 – 433PubMedGoogle Scholar
  2. 2.
    Levin DL, Connelly RR, Devesa SS (1981) Demographic characteristics of cancer of the pancreas: mortality, incidence, and survival. Cancer 47:1456–1468PubMedCrossRefGoogle Scholar
  3. 3.
    Lin RS, Kessler II (1981) A multifactorial model for pancreatic cancer in man. Epidemiologie evidence. JAMA 245:147–152PubMedCrossRefGoogle Scholar
  4. 4.
    Clemente F, Scemama JL, Ruellan C, Estival A (1986) Human pancreatic cancer cells in culture: an approach to their hormonal regulation and differentiation. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 28–39Google Scholar
  5. 5.
    Benz C, Hollander C, Miller B (1986) Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res 31:2276–2281Google Scholar
  6. 6.
    Serrano MJ, Liebow C, Reilly C, Schally AV (1988) LH-RH analog causes direct inhibition of growth of pancreatic cancer cells in culture. Pancreas 3:617Google Scholar
  7. 7.
    Lacaine F, Houry S, Clough K, Lointier P, Huguier M (1986) Is pancreatic tumor growth inhibited by sex hormones? An experimental study in hamster. Eur Surg Res 18:22Google Scholar
  8. 8.
    Sumi C, Longnecker DS, Roebuck BD, Brinck-Johnsen T (1989) Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine. Cancer Res 49:2332–2336PubMedGoogle Scholar
  9. 9.
    Longnecker DS(i986) Experimental pancreatic cancer: role of species, age, sex and diet. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 78–92Google Scholar
  10. 10.
    Greenway B, Duke D, Pym B, Iqbal MJ, Johnson PJ, Williams R (1982) The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br J Surg 69:595–597PubMedCrossRefGoogle Scholar
  11. 11.
    Kyriazis AP, Kyriazis AA (1986) Transplantation and biological behavior of human pancreatic cancer in the nude mouse. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 93 –104Google Scholar
  12. 12.
    Redding TW, Schally AV (1984) Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypotalamic hormones. Proc Natl Acad Sci USA 81:248 – 252PubMedCrossRefGoogle Scholar
  13. 13.
    Szende K, Srkalovic G, Schally AV, Lapis K, Groot K (1990) Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Cancer 65:2279 – 2290PubMedCrossRefGoogle Scholar
  14. 14.
    Greenway B, Igbal MJ, Johnson PL, Williams R (1981) Oestrogen receptor proteins in malignant and fetal pancreas. Br. Med J 283:751 – 753CrossRefGoogle Scholar
  15. 15.
    Satake K, Yoshimoto T, Mukai R, Umeyama K (1982) Estrogen receptors in 7,12-dimethylbenz(a)-anthracene (DMBA) induced pancreatic carcinoma in rats and in human pancreatic carcinoma. Clin Oncol 8:49 – 54PubMedGoogle Scholar
  16. 16.
    Benz C, Wisnitzer I, Benz C (1984) Steroid binding and cytoxicity in cultured human pancreatic carcinomas. Prog Cancer Res Ther 31:223–228Google Scholar
  17. 17.
    Pousette A, Appelgren L, Carlstrom K, Skoldefors H, Wilking N, Theve NO (1984) Purification and characterization of an estradiol-17-b-finding macromolecule in rat pancreas. Acta Chem Scand B38:407 – 414CrossRefGoogle Scholar
  18. 18.
    Lointier P, Pezet D, Ferrier C, Chipponi J, Saez S (1988) Rôle des sites spécifiques de liaison du tamoxifène (TAM) et distincts des récepteurs aux oestrogènes (RE) dans l’inhibition de la croissance in vitro d’un adénocarcinome pancréatique humain (MIA PaCa-2) par le TAM. Gastroenterol Clin Biol 11:264Google Scholar
  19. 19.
    Corbishley TP, Igbal MJ, Johnson PJ, Williams R (1984) Progesteone receptors in malignant and foetal pancreatic tissue. IRCS Med Sci 12:575–576Google Scholar
  20. 20.
    Grenway BA (1987) Carcinoma of the exocrine pancreas: a sex hormone responsive tumor? Br J Surg74:441–442CrossRefGoogle Scholar
  21. 21.
    Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R (1986) Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer 57:1992–1995PubMedCrossRefGoogle Scholar
  22. 22.
    Andren-Sandberg A (1989) Androgen influence on exocrine pancreatic cancer. Int J Pan-creatology 4:363 – 369Google Scholar
  23. 23.
    Greenway BA, Iqbal MJ, Johnson PJ, Williams R (1983) Low serum testosterone concentrations in patients with carcinoma of the pancreas. Br J Med J 286:93–95CrossRefGoogle Scholar
  24. 24.
    Robles-Diaz G, Diaz-Sanchez V, Morales M, Gulias A, Fernandez Del Castillo C (1990) Le rapport testosterone/dihydrostestosterone (T/DHT) et testosterone/androstenedione (T/A) dans le cancer du pancreas. Gastroenterol Clin Biol 14: A8Google Scholar
  25. 25.
    Friess H, Buchler M, Kiesel L, Kruger M, Beger HG (1991) LH-RH receptors in the human pancreas. Int J Pancreatol 10:151 –159PubMedGoogle Scholar
  26. 26.
    Fekete M, Zalatnai A, Comaru-Schally AM, Schally AV (1989) Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas 4:521–528PubMedCrossRefGoogle Scholar
  27. 27.
    Theve NO, Pousette A, Carlstrum K (1983) Adenocarcinoma of the pancreas — a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 115:244–248Google Scholar
  28. 28.
    Tonnesen K, Kamp-Jensen M (1986) Antioestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol 12:69 – 70PubMedGoogle Scholar
  29. 29.
    Crowson MC, Dorbella A, Rolfe EB, Fielding JWL (1986) A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol 12:335–336PubMedGoogle Scholar
  30. 30.
    Wong A, Chan A, Arthur K (1987) Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 71:749 – 750PubMedGoogle Scholar
  31. 31.
    Scheithauer W, Kornek G, Haider K, Depisch D (1990) Unresponsiveness of pancreatic adeno-carcinoma to anti-oestrogen therapy. Eur J Cancer 26:851–852PubMedCrossRefGoogle Scholar
  32. 32.
    Gonzales-Marcena D, Ibarra-Olmos MA, Garcia-Carrasaco F, Gutierrez-Samperio C, Comaru-Schally AM, Schally AV (1989) Influence of (D-Trp6)-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother 43:313–317CrossRefGoogle Scholar
  33. 33.
    Frieb H, Buchler M,Kruger M, Beger HG (1992) Treatment of duct carcinoma of the pancreas with the LH-RH analog buserelin. Pancreas 7:516–521CrossRefGoogle Scholar
  34. 34.
    Keating JJ, Johnson PJ, Cochrane MG et al (1989) A prospective randomized controlled-trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 60 : 789–792PubMedCrossRefGoogle Scholar
  35. 35.
    Bakkevold KE, Pettersen A, Arnesjo B, Espehaug B (1990) Tamoxifen therapy in unresect able adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 77:725–730PubMedCrossRefGoogle Scholar
  36. 36.
    Huguier M, Samama G, Testart J et al. (1991) L’hormonothérapie dans les cancers du pancréas exocrine: une étude de l’AURC, l’ARC et de l’ARCIF Gastroenterol Clin Biol 15:169Google Scholar
  37. 37.
    Mainz DL, Black O, Webster PD (1973) Hormonal control of pancreas growth. J Clin Invest 52:2300–2304PubMedCrossRefGoogle Scholar
  38. 38.
    Dembinski AB, Johnson LR (1980) Stimulation of pancreatic grow secretin, coerulein and pentagastrin. Endocrinology 106:323 – 328PubMedCrossRefGoogle Scholar
  39. 39.
    Balas D, Senegas Balas F, Pradayrol (1985) Long-term comparative effect of chlecystokinin and gastrin on mouse stomach, antrum, intestine, and exocrine pancreas. Am J Anat 174: 27–43PubMedCrossRefGoogle Scholar
  40. 40.
    Lehy T, Dubrasquet M, Brazeua P, Bonfils S (1982) Inhibitory effect of prolonged administration of long-acting somatostatin on gastrin-stimulated fundic epithelial cell growth in the rat. Digestion 24:246–255PubMedCrossRefGoogle Scholar
  41. 41.
    Morisset J, Genki P, Lord A, Solomon TE (1982) Effects of chronic administration of somatostatin on rat exocrine pancreas. Regul Pept 4:49–58PubMedCrossRefGoogle Scholar
  42. 42.
    Towsend CM, Singh P, Thompson JC (1986) Gastrointestinal hormones and gastrointestinal and pancreatic carcinomas. Gastroenterology 91:1002–1006Google Scholar
  43. 43.
    Liehr RM, Melnykovych G, Solomon TE (1990) Growth effects of regulatory peptides on human pancreatic cancer lines PANC-1 and MIA Pa-Ca-2. Gastroenterology 98:1666 –1674PubMedGoogle Scholar
  44. 44.
    Smith JP, Solomon TE, Bagheri S, Kramer S (1990) Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 11:1377–1384CrossRefGoogle Scholar
  45. 45.
    Pour PM (1986) Experimental pancreatic cancer in hamsters: etiology, comparative pathology and immunology. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 60–77Google Scholar
  46. 46.
    Longnecker DS (1991) Hormones and pancreatic cancer. Int J Pancratol 9:81–86Google Scholar
  47. 47.
    Douglas BR, Woutersen RA, Jansen JBMJ, Dejong AJL, Rovati LC, Lamers CBHW (1989) Influence of cholecystokinin antagonist on the effects of cholecystolinin and bombesin on aszaserine-induced lesions in rat pancreas. Gastroenterology 96:462–469PubMedGoogle Scholar
  48. 48.
    Nagain C, Roze C (1991) Les récepteurs de la cholecystokinine. Gastroenterol Clin Biol 15:735–743PubMedGoogle Scholar
  49. 49.
    Estival A, Clémente F, Ribet A (1981) Adenocarcinoma of the human exocrine pancreas: presence of secretin and caerulein receptors. Biochem. Biophys Res Common 102: 1336–1341CrossRefGoogle Scholar
  50. 50.
    Edwards BF, Redding TW, Schally AV (1989) The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa). Int J Pancreatol 5:191 - 201PubMedGoogle Scholar
  51. 51.
    Axelson J, Ihse I, Hakanson R (1992) Pancreatic cancer: the role of cholecystokinin? Scand J Gastroenterol 27:993-998PubMedCrossRefGoogle Scholar
  52. 52.
    Takacs T, PAP A (1991) Perspective of CCK antagonists in pancreatic research. Int J Pancreatol 10:1-8PubMedGoogle Scholar
  53. 53.
    Maani R, Townsend CM, Gomez G, Thompson JC, Singh P (1988) A potent CCK receptor antagonist (L-364, 718) inhibits the growth of human pancreatic cancer in nude mice. Gastroenterology 94-274 (abstract)Google Scholar
  54. 54.
    Stace NH, Palmer TJ, Vaja S, Dowling RH (1987) Longterm pancreticobiliary diversion stimulates hyperplastic and adenomatous noduels in the rat pancreas: a new model for spontaneous tumour formation. Gut 28 [Suppl] : 265 - 268PubMedCrossRefGoogle Scholar
  55. 55.
    Scemama JL, De Vries L, Pradayrol L, Seva C, Tronchere H, Vaysse N (1989) Cholecystokinin and gastrin peptides stimulate ODC activity in a rat pancreatic cell line. Am J Physiol 256:6846-850Google Scholar
  56. 56.
    Townsend CM Jr, Franklin RB, Watson LC, Glass EJ, Thompson JC (1981) Stimulation of pancreatic cancer growth by caerulein and secretin. Surg Forum 32:228 - 229Google Scholar
  57. 57.
    Howatson AG, Carter DC (1987) Pancreatic carcinogenesis: effect of secretin in the hamster-nitrosamine model. J Natl Cancer Inst 78:101-105PubMedGoogle Scholar
  58. 58.
    Poston GJ, Yao CZ, Upp JR, Alexander RW, Townsend CM, Thompson JC (1988) Vasoactive intestinal peptide inhibits the growth of hamster pancreatic cancer but not human pancreatic cancer in vivo. Pancreas 3:439 - 443PubMedCrossRefGoogle Scholar
  59. 59.
    Lhoste EF, Longnecker DS (1987) Effect of bombesin and caerulein on early stages of carcinogenesis induced by azaserine in the rat pancreas. Cancer Res 47:3273–3277PubMedGoogle Scholar
  60. 60.
    Alexander RW, Upp JR, Poston GJ, Townsend CM, Singh P, Thompson JC (1988) Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice. Pancreas 3:297–302PubMedCrossRefGoogle Scholar
  61. 61.
    Viguerie N, Tahiri-Jouti N, Ayral AM et al. (1988) Somatostatine et prolifération cellulaire-antagonisme somatostaine-EGF sur une lignée pancréatique tumorale de rat AR4-2J. Gastroenterol Clin Biol 12: A116Google Scholar
  62. 62.
    Hajri A, Aphrahamian M, Balboni G, Koenig M, Damge C (1990) Effet de la somatostatine-retard, la sandostatine, sur une tumeur pancréatique acinaire transplatée chez le rat en fonction du stade de la croissance tumorale. Gastroenterol Clin Biol 14: A56Google Scholar
  63. 63.
    Poston GJ, Lawrence JP, Singh P, Towsend CM, Thompson JC (1988) Inhibition of growth of human pancreatic cancer in vivo hy somatostatin and tamoxifen. Br J Surg 75:1257Google Scholar
  64. 64.
    Hierowski MT, Liebow C, Dusapin K, Schally AV (1985) Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett 179:252–256PubMedCrossRefGoogle Scholar
  65. 65.
    Reubi JC, Horisberger U, Essed CE, Jeekel J, Klijn JG, Lamberts SW (1988) Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95 : 760–763PubMedGoogle Scholar
  66. 66.
    Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R (1992) Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Cancer 69:648–650PubMedCrossRefGoogle Scholar
  67. 67.
    Abruzzese JL, Gholson CF, Daugherty K, Larson E, Dubrow R, Berlin R, Levin B (1992) A pilot clinical trial of cholecystokinin receptor antagonist MK 329 in patients with advanced pancreatic cancer. Pancreas 7:165–171CrossRefGoogle Scholar
  68. 68.
    Korc M (1986) Epidermal growth factor receptor: its role in pancreatic cancer. In: Delmont JP (ed) Cancer of the exocrine pancreas. Karger, Basel, pp 40–47Google Scholar
  69. 69.
    Korc M (1991) Growth factors and pancreatic cancer. Int J Pancreatol 9:87–91PubMedGoogle Scholar
  70. 70.
    Glinsmann-Gibson BJ, Korc M (1991) Regulation of transforming growth factor-alpha mRNA expression in T3M4 human pancreatic carcinoma cells. Pancreas 6:162–149CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • F. X. Caroli-Bosc
  • P. Hastier
  • A. G. Harris
  • P. Gaudray
  • D. Balas
  • J. P. Delmont

There are no affiliations available

Personalised recommendations